{
  "docId": "019de073-bad9-7032-8a81-e4ebe475dedb",
  "docSlug": "033dbe0b064db9b5c6a8c7c8096ccb5c",
  "documentTitle": "Genprex | Investor Presentation Deck | 44 slides",
  "authorId": "genprex",
  "authorName": "Genprex",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 44,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines a clinical trial methodology comparing a novel combination therapy against a standard of care control arm.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-bad9-7032-8a81-e4ebe475dedb/21",
  "deckHref": "/decks/019de073-bad9-7032-8a81-e4ebe475dedb",
  "deckJsonHref": "/decks/019de073-bad9-7032-8a81-e4ebe475dedb.json",
  "deckAnchorHref": "/decks/019de073-bad9-7032-8a81-e4ebe475dedb#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.94,
        "x": 0.03,
        "y": 0.48
      },
      "kind": "diagram",
      "text": "Measuring Time From First Progression To Second Progression: REQORSA + Keytruda vs. Docetaxel +/- Ramucirumab",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a385819a-7150-41ff-8781-59b897025a76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.03,
        "y": 0.09
      },
      "kind": "list",
      "text": "FDA Fast Track Designation (received December 2021)\nPatients with advanced NSCLC whose disease progressed after treatment with Keytruda\n~10 U.S. sites\n~156 patients\nInterim analysis at 50 events\nExpect to complete Phase 1 by mid-2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c84611d7-0242-46d8-83eb-40a7211230f7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.53,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "REQORSA in combination with Merck & Co's Keytruda for NSCLC",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b8309da-6fd3-4cb9-a5ea-b34b98bd865a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.35,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "GENERAL STUDY CHARACTERISTICS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "48b257a6-20f9-49c8-8393-bd401fe12fcf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.25,
        "x": 0.57,
        "y": 0.08
      },
      "kind": "title",
      "text": "Acclaim-2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4b2752d-403e-4bb8-9f27-0ea2da306317",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "d0b04756-5131-4fe2-ab55-9202c868e53e",
      "evidence": "Visual representation of study phases and treatment arms",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}